The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.

The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.

The pharmacokinetics of 5-fluorouracil (5FU) following its administration via the hepatic artery in conjunction with biodegradable albumin microspheres and angiotensin II have been studied. Peripheral venous concentrations of 5FU are lower and plasma clearance values higher following intrahepatic ar...

Full description

Bibliographic Details
Main Authors: Goldberg, J. A., Kerr, D. J., Watson, D. G., Willmott, N., Bates, C. D., McKillop, J. H., McArdle, C. S.
Format: Online
Language:English
Published: 1990
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971687/
id pubmed-1971687
recordtype oai_dc
spelling pubmed-19716872009-09-10 The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases. Goldberg, J. A. Kerr, D. J. Watson, D. G. Willmott, N. Bates, C. D. McKillop, J. H. McArdle, C. S. Research Article The pharmacokinetics of 5-fluorouracil (5FU) following its administration via the hepatic artery in conjunction with biodegradable albumin microspheres and angiotensin II have been studied. Peripheral venous concentrations of 5FU are lower and plasma clearance values higher following intrahepatic arterial administration compared with a similar dose administered by intravenous infusion over both 2 h and 24 h. For the 2 h drug infusions, plasma 5FU concentrations following co-treatment with angiotensin II and microspheres via the hepatic artery were intermediate between those of arterial and venous infusions of 5FU alone. There was a trend towards the peak plasma drug concentrations and the area under the plasma concentration-time curve (AUC) being significantly lower following co-treatment with angiotensin II and microspheres compared with intra-arterial and intravenous infusions of 5FU over 24 h. Co-administration of 5FU, angiotensin II and microspheres via the hepatic artery may reduce drug exposure in the systemic compartment and therefore may increase the therapeutic ratio of 5FU administration via the hepatic artery. 1990-06 /pmc/articles/PMC1971687/ /pubmed/2372496 Text en
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Goldberg, J. A.
Kerr, D. J.
Watson, D. G.
Willmott, N.
Bates, C. D.
McKillop, J. H.
McArdle, C. S.
spellingShingle Goldberg, J. A.
Kerr, D. J.
Watson, D. G.
Willmott, N.
Bates, C. D.
McKillop, J. H.
McArdle, C. S.
The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
author_facet Goldberg, J. A.
Kerr, D. J.
Watson, D. G.
Willmott, N.
Bates, C. D.
McKillop, J. H.
McArdle, C. S.
author_sort Goldberg, J. A.
title The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
title_short The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
title_full The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
title_fullStr The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
title_full_unstemmed The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
title_sort pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
description The pharmacokinetics of 5-fluorouracil (5FU) following its administration via the hepatic artery in conjunction with biodegradable albumin microspheres and angiotensin II have been studied. Peripheral venous concentrations of 5FU are lower and plasma clearance values higher following intrahepatic arterial administration compared with a similar dose administered by intravenous infusion over both 2 h and 24 h. For the 2 h drug infusions, plasma 5FU concentrations following co-treatment with angiotensin II and microspheres via the hepatic artery were intermediate between those of arterial and venous infusions of 5FU alone. There was a trend towards the peak plasma drug concentrations and the area under the plasma concentration-time curve (AUC) being significantly lower following co-treatment with angiotensin II and microspheres compared with intra-arterial and intravenous infusions of 5FU over 24 h. Co-administration of 5FU, angiotensin II and microspheres via the hepatic artery may reduce drug exposure in the systemic compartment and therefore may increase the therapeutic ratio of 5FU administration via the hepatic artery.
publishDate 1990
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971687/
_version_ 1611400211062587392

Similar Items